Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Clinical Trials Software Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The Clinical Trials Software Market was valued at USD 1.26 billion in 2023, and is projected to reach USD 3.13 billion by 2029, rising at a CAGR of 16.38%. The global clinical trials software market is set to grow due to rapid development in clinical trials and the increasing attention toward patient-centric approaches.
The global clinical trials software market report consists of exclusive data from 36 vendors. Dassault Systemes, BSI Business System Integration AG, Clario., IQVIA, Laboratory Corporation of America Holdings, and Oracle Corporation are some leading companies. These vendors continuously develop innovative clinical trial software platforms and associated tools and maintain their brand image in the global market. Software launches, promotion activities, product development and advancements, collaborations, and partnerships also strengthen their position in the market. These market players are expected to dominate with continued engagement, innovation, and business strategic initiatives like M&A, collaboration, and partnership.

RECENT VENDORS ACTIVITIES
KEY TAKEAWAYS
MARKET TRENDS & DRIVERS
Growing Attention to Enhance Data Privacy and Security
Clinical trials are becoming more advanced, and integrating new digital tools, technologies, and software is essential. However, with the growing attention towards data privacy and security, future clinical database software is incorporating advanced security features while using clinical trial software solutions. In recent years, advanced features have gained huge attention in the clinical trials software industry, like sophisticated encryption techniques, data security regulations, and blockchain technologies for immutable data records.
Rapid Development in Clinical Trials
Innovations are revolutionizing the clinical trials industry and delivering potential growth opportunities. In addition, technology advancement and integration accelerate the development of personalized medicines and treatments, remote patient monitoring, and hybrid & fully decentralized clinical trials. Machine learning (ML) and artificial intelligence (AI) are rapidly integrated into numerous drug discovery and development procedures. AI facilitates drug development, speeding up operations, improving trial efficiency, increasing the precision of data analysis, and automating testing. Moreover, the expanding hybrid and decentralized trial models and associated tools and technologies create huge opportunities for the clinical trials software market.
Reduction in Trials Expenses with Clinical Trials Software
Incorporating clinical trial software is an effective approach, enabling significant cost savings for organizers and sponsors. Clinical trials software solution reduced around 30% of overall clinical trials cost. By reducing reliance on physical sites or in-person visits, with a decentralized clinical trials model, clinical trials software streamlines research procedures, decreases overhead costs, and saves on patient travel, site operations, patient monitoring visits, shortened enrolment periods, reduced patient dropout, expedited data collection, and accuracy. Clinical trials are notoriously complex, lengthy, and expensive, imposing a significant financial burden on healthcare companies. Clinical trial software features like EDC enhanced clinical trial and patient data and reduced associated traditional paper-based documents. ePRO and eCOA enhanced patient health-related data, reducing human errors and associated costs. eConsent has become a major choice for reducing paper-based and traditional consent forms and patient attitudes toward participation in clinical trials.
INDUSTRY RESTRAINTS
Lack of Adoption & Acceptance
During the COVID-19 pandemic, the popularity and awareness of clinical trial software have increased significantly. However, the acceptance of clinical trial software in clinical studies is still lower. Several factors hamper the adoption of clinical trial software, including the lack of supportive digital infrastructure, the required investment cost, the return on investment in clinical trials, and the lack of resources to handle them. Clinical trial sites already face huge costs and employee/workforce burdens, where incorporating clinical trial software poses an additional burden. Several factors need to be considered when incorporating clinical trial software, which requires huge investment costs, including features and functionality, technology stack, regulatory compliance, development team, integration, maintenance, and support.
GEOGRAPHICAL ANALYSIS
North America held the largest market share, over 33% of the global clinical trials software market. North America dominates the market by adopting advanced technologies and digital tools in clinical studies. The U.S. has a high adoption rate of decentralized clinical trials in North America, with a strong foundation and wide acceptance of advanced clinical trial models. This existing infrastructure and willingness to embrace innovative technologies have positioned North America as a global clinical trials software market leader. Favorable guidelines, government support, and rising expenditure are key factors contributing to the growth of clinical research in the US. The US and Canada are the top two countries in North America, and they conduct many decentralized clinical trials and contribute to market growth.
COMPETITIVE LANDSCAPE
Key Vendors
Other Prominent Vendors
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 151 |
| Forecast Period | 2023 - 2029 |
| Estimated Market Value (USD) in 2023 | $1.26 Billion |
| Forecasted Market Value (USD) by 2029 | $3.13 Billion |
| Compound Annual Growth Rate | 16.3% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1: Clinical Trials Software Market Overview
Chapter 2: Clinical Trials Software Market Market
Chapter 3:Clinical Trials Software Market Prospects & Opportunities
Chapter 4: Clinical Trials Software Market Segmentation Data
Global: Projected Revenue by Deployment Type (2020-2029; $ Millions)
Global: Projected Revenue by Delivery (2020-2029; $ Millions)
Global: Projected Revenue by Feature (2020-2029; $ Millions)
Global: Projected Revenue by End-user (2020-2029; $ Millions)
Chapter 5: Key Regions Overview
North America: Projected Revenue of Clinical Trials Software Market (2020-2029; $ Millions)
Europe: Projected Revenue of Clinical Trials Software Market (2020-2029; $ Millions)
APAC: Projected Revenue of Clinical Trials Software Market (2020-2029; $ Millions)
Latin America: Projected Revenue of Clinical Trials Software Market (2020-2029; $ Millions)
Middle East & Africa: Projected Revenue of Clinical Trials Software Market (2020-2029; $ Millions)
Chapter 6: Clinical Trials Software Market Industry Overview
For more information about this report visit https://www.researchandmarkets.com/r/1iboj0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment